肝硬化腹水管理新策略——长期白蛋白治疗

doi:10.3969/j.issn.1006-5725.2024.05.001

Abstract

Abstract:

Ascites is the most frequent decompensating event of cirrhosis. At present， ascites recurs at a high rate due to lack of effective management strategy and is frequently complicated with spontaneous bacterial peritonitis， hepatorenal syndrome， and liver failure， which increase the fatality rate. Albumin treatment for hepatocirrhosic ascites has a long history， but it is limited as an acute or short?term treatment. In contrast， long?term albumin administration represents a completely different treatment paradigm. Results from several recent clinical studies indicate that long?term albumin treatment can be able to modify the disease courses of some decompensated cirrhosis when albumin is given at a sufficient dose for a sufficient time. In this review， we analyze the available data acquired from long?term albumin treatments， trying to establish a secure and effective management scheme involving maximal target population， albumin dose， administration time， and standards for albumin withdrawal， and thus provide references for the clinical practice.

Key words: long?term albumin, effective albumin, ascites, decompensated cirrhosis

CLC Number:

R657.3+1

lei WEN,Huihong YU,Xianlong LING. A new strategy for the management of ascites in liver cirrhosis： A long⁃term albumin treatment[J]. The Journal of Practical Medicine, 2024, 40(5): 591-595.

References 33

1	GINES P， KRAG A， ABRALDES J G，et al. Liver cirrhosis［J］.Lancet， 2021， 398（10308）：1359⁃1376. doi:10.1016/s0140-6736(21)01374-x doi: 10.1016/s0140-6736(21)01374-x
2	MA C， QIAN A S， NGUYEN N H，et al. Trends in the economic burden of chronic liver diseases and cirrhosis in the United States：1996-2016［J］. Am J Gastroenterol， 2021， 116（10）：2060⁃2067. doi:10.14309/ajg.0000000000001292 doi: 10.14309/ajg.0000000000001292
3	D′AMICO G， GARCIA-TSAO G， PAGLIARO L.Natural history and prognostic in Dicators of survival in cirrhosis： a systematic review of 118 studies［J］. J Hepatol， 2006，44（1）：217⁃231. doi:10.1016/j.jhep.2005.10.013 doi: 10.1016/j.jhep.2005.10.013
4	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis［J］. J Hepatol，2018，69（2）：406⁃460. doi:10.1016/j.jhep.2018.08.009 doi: 10.1016/j.jhep.2018.08.009
5	BIGGINS S W， ANGELI P， GARCIA-TSAO G， et al. Diagnosis， evaluation， and management of ascites， spontaneous bacterial peritonitis and hepatorenal syndrome： 2021 Practice Guidance by the American Association for the Study of Liver Diseases［J］. Hepatology， 2021，74（2）：1014⁃1048. doi:10.1002/hep.31884 doi: 10.1002/hep.31884
6	GINES P， SOLA E， ANGELI P，et al. Kamath PS. Hepatorenal syndrome［J］. Nat Rev Dis Primers， 2018，8（1）：4-23. doi:10.1038/s41572-018-0022-7 doi: 10.1038/s41572-018-0022-7
7	DE SIMONE G， DI MASI A， ASCENZI P. Serum Albumin： A Multifaced Enzyme［J］. Int J Mol Sci， 2021，22（18）：22-35. doi:10.3390/ijms221810086 doi: 10.3390/ijms221810086
8	BELINSKAIA D A， VORONINA P A， GONCHAROV N V. Integrative Role of Albumin： Evolutionary，Biochemical and Pathophysiological Aspects［J］. J Evol Biochem Physiol， 2021，57（6）：1419-1448. doi:10.1134/s002209302106020x doi: 10.1134/s002209302106020x
9	BERNARDI M， ANGELI P， CLARIA J， et al. Albumin in decompensated cirrhosis： new concepts and perspectives［J］. Gut，2020，69（6）：1127⁃1138. doi:10.1136/gutjnl-2019-318843 doi: 10.1136/gutjnl-2019-318843
10	NALDI M， BALDASSARRE M， DOMENICALI M，et al. Structural and functional integrity of human serum albumin： analytical approaches and clinical relevance in patients with liver cirrhosis［J］. J Pharm Biomed Anal， 2017，144：138⁃153. doi:10.1016/j.jpba.2017.04.023 doi: 10.1016/j.jpba.2017.04.023
11	D’AMICO G， MARUZZELLI L， AIROLDI A，et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology［J］. J Hepatol， 2021，75（6）：1355-1366. doi:10.1016/j.jhep.2021.07.018 doi: 10.1016/j.jhep.2021.07.018
12	CLARIA J， STAUBER R E， COENRAAD M J，et al. Systemic inflammation in decompensated cirrhosis：Characterization and role in acute-on-chronic liver failure［J］. Hepatology， 2016，64（4）：1249⁃1264. doi:10.1002/hep.28740 doi: 10.1002/hep.28740
13	BALDASSARRE M， NALDI M， ZACCHERINI G，et al. Determination of effective albumin in patients with decompensated cirrhosis：clinical and prognostic implications［J］. Hepatology， 2021，74（4）：2058⁃2073. doi:10.1002/hep.31798 doi: 10.1002/hep.31798
14	DAS S， MARAS J S， HUSSAIN M S，et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis［J］. Hepatology， 2017，65（2）：631⁃646. doi:10.1002/hep.28897 doi: 10.1002/hep.28897
15	ALCARAZ-QUILES J， CASULLERAS M， OETTL K，et al. Oxidized albumin triggers a cytokine storm in leukocytes through p38 mitogen-activated protein kinase： role in systemic inflammation in decompensated cirrhosis［J］. Hepatology， 2018，68（5）：1937⁃1952. doi:10.1002/hep.30135 doi: 10.1002/hep.30135
16	JALAN R， BERNARDI M. Effective albumin concentration and cirrhosis mortality： from concept to reality［J］. J Hepatol， 2013，59（3）：918-920. doi:10.1016/j.jhep.2013.08.001 doi: 10.1016/j.jhep.2013.08.001
17	GARCIA-MARTINEZ R， CARACENI P， BERNARDI M，et al.Albumin： pathophysiologic basis of its role in the treatment of cirrhosis and its complications［J］. Hepatology， 2013，58（5）：1836⁃1846. doi:10.1002/hep.26338 doi: 10.1002/hep.26338
18	FERNANDEZ J， CLARIA J， AMOROS A，et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis［J］. Gastroenterology， 2019，157（1）：149⁃162. doi:10.1053/j.gastro.2019.05.040 doi: 10.1053/j.gastro.2019.05.040
19	BORTOLUZZI A， CEOLOTTO G， GOLA E，et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites： molecular mechanisms［J］. Hepatology， 2013，57（1）：266⁃276. doi:10.1002/hep.26021 doi: 10.1002/hep.26021
20	CHINA L， MAINI A， SKENE S S，et al. Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease［J］. Clin Gastroenterol Hepatol， 2018，16（5）：738⁃747. doi:10.1016/j.cgh.2017.08.027 doi: 10.1016/j.cgh.2017.08.027
21	FERNANDEZ J， ANGELI P， TREBICKA J，et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis［J］. Clin Gastroenterol Hepatol， 2019，18（4）：963⁃973. doi:10.1016/j.cgh.2019.07.055 doi: 10.1016/j.cgh.2019.07.055
22	CASULLERAS M， FLORES-COSTA R， DURAN-GUELL M，et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis［J］. Sci Transl Med， 2020，12（566）：426-439. doi:10.1126/scitranslmed.aax5135 doi: 10.1126/scitranslmed.aax5135
23	CARACENI P， RIGGIO O， ANGELI P，et al. Long-term albumin administration in decompensated cirrhosis （ANSWER）： an open-label randomised trial［J］. Lancet， 2018， 391（10138）：2417⁃2429.
24	CARACENI P， TUFONI M， ZACCHERINI G，et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites［J］. J Hepatol， 2021，74（2）：340⁃349.
25	DI PASCOLI M， FASOLATO S， PIANO S，et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites［J］. Liver Int， 2019，39（1）：98⁃105. doi:10.1111/liv.13968 doi: 10.1111/liv.13968
26	SOLA E， SOLE C， SIMON-TALERO M，et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation：A randomized placebo-controlled trial［J］. J Hepatol， 2018，69（6）：1250⁃1259. doi:10.1016/j.jhep.2018.08.006 doi: 10.1016/j.jhep.2018.08.006
27	CHINA L， FREEMANTLE N， FORREST E，et al.A randomized trial of albumin infusions in hospitalized patients with cirrhosis［J］. N Engl J Med， 2021，384（9）：808⁃817. doi:10.1056/nejmoa2022166 doi: 10.1056/nejmoa2022166
28	Italian Association for the Study of the Liver （AISF）. Portal hypertension and ascites： patient-and population-centered clinical practice guidelines by the Italian Association for the Study of the Liver （AISF）［J］. Dig Liver Dis， 2021， 53（9）：1089⁃1104. doi:10.1016/j.dld.2021.06.021 doi: 10.1016/j.dld.2021.06.021
29	VIRENDRA S， ARKA D， ROHIT M，et al. Asia⁃Pacifc association for study of liver guidelines on management of ascites in liver disease［J］. Hepatol Int， 2023，17（4）：792-826. doi:10.1007/s12072-023-10536-7 doi: 10.1007/s12072-023-10536-7
30	BAI Z H， MENDEZ-SANCHEZ N， ROMEIRO F G，et al. Use of albumin infusion for cirrhosis-related complications： An international position statement［J］. JHEP Rep， 2023，5（8）：212-228. doi:10.1016/j.jhepr.2023.100785 doi: 10.1016/j.jhepr.2023.100785
31	TADA S， YASUKAWA K， YATOMI Y， et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin［J］. Pract Lab Med， 2022，31：e00281. doi:10.1016/j.plabm.2022.e00281 doi: 10.1016/j.plabm.2022.e00281
32	FERNANDEZ J， CLARIA J， AMOROS A， et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis［J］. Gastroenterology， 2019，157（1）：149⁃162. doi:10.1053/j.gastro.2019.05.040 doi: 10.1053/j.gastro.2019.05.040
33	CAMPION E W， DELABRY L O， GLYNN R J. The effect of age on serum albumin level in healthy males：report from the normative aging study［J］. Gerontol， 1988，43（1）：M18⁃20. doi:10.1093/geronj/43.1.m18 doi: 10.1093/geronj/43.1.m18

[1]	Qingqing WANG,Jie DING,Haiwen LI,Zhijian DONG,Yiying WANG,Siqi LIU,Guoji CHANG,Lijuan HUA,Huayi CHEN,Shenghao LI,Yongrui. YANG. Analysis of factors influencing short⁃term adverse clinical outcome in cirrhotic patients with grade 2/3 ascites [J]. The Journal of Practical Medicine, 2024, 40(8): 1114-1120.
[2]	Haitao TANG,Xian WANG,Tingxia CHAO,Fengmei WANG,Wenling JIA,Chunhui LIANG,Wenhua. ZHANG. Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients with decompensated cirrhosis [J]. The Journal of Practical Medicine, 2023, 39(24): 3249-3254.
[3]	ZHANG Meng, LIU Jiao, CHEN Yi, LI Yesheng, HUANG Yangqing. A randomized controlled trial of tolvaptan in the treatment of cirrhotic ascites during the perioperative pe⁃ riod [J]. The Journal of Practical Medicine, 2021, 37(16): 2137-2141.
[4]	WU Huijie, XU Haiying, ZHANG Lingyun, QIU Huibing, YAO Fan. . Effect of intracavitary infusion of elemene combined with nedaplatin on clinical efficacy and quality of life of patients with malignant ascites [J]. The Journal of Practical Medicine, 2021, 37(14): 1857-1860.

A new strategy for the management of ascites in liver cirrhosis： A long⁃term albumin treatment

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 4

Recommended Articles

Metrics

Comments